Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
- 1 January 2001
- journal article
- review article
- Published by Elsevier BV in Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale
- Vol. 119 (1), 64S-94S
- https://doi.org/10.1378/chest.119.1_suppl.64s
Abstract
No abstract availableThis publication has 78 references indexed in Scilit:
- Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarctionThe American Journal of Cardiology, 1996
- Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapyThe American Journal of Cardiology, 1996
- Heparins, coumarin, and bone densityThe Lancet, 1991
- Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormalityAmerican Heart Journal, 1990
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Role of heparin after intravenous thrombolytic therapy for acute myocardial infarctionThe American Journal of Cardiology, 1987
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- The effects of phospholipid and factor Va on the inhibition of Factor Xa by antithrombin IIIBiochemical and Biophysical Research Communications, 1979
- Heparin therapy: A randomized prospective studyAmerican Heart Journal, 1979
- The separation of active and inactive forms of heparinBiochemical and Biophysical Research Communications, 1976